Skip to Content
Jump to the top of the page

Showing 1220 – 1230 of 1304 results

  • TWFG Inc Initiation

    William Blair initiated research coverage of TWFG, Inc. (TWFG $26.30), an independent distributor of personal and commercial insurance.

  • APi Group Corporation Initiation

    William Blair initiated research coverage of APi Group Corporation (APG $37.65), the global leader in life safety services, with a total addressable market that is estimated to exceed $150 billion.

  • Solid Biosciences Inc Initiation

    William Blair initiated research coverage of Solid Biosciences Inc. (SLDB $13.57), a development-stage biopharmaceutical company focused on gene therapies for rare neuromuscular and cardiac diseases.

  • Vigil Neuroscience Inc Initiation

    William Blair initiated research coverage of Vigil Neuroscience, Inc. (VIGL $2.47), a clinical-stage biopharma focused on developing microglial-targeting therapeutics by leveraging genetic insights into degenerative disorders of the central nervous system (CNS).

  • Shift4 Payments Inc Initiation

    William Blair initiated research coverage of Shift4 Payments, Inc. (FOUR $83.10), a leading merchant acquirer or payment service provider (PSP). Shift4 operates four complementary businesses: a proprietary gateway, a leading venue payments and ticketing business, an emerging software-enabled POS, and a cross-border e-commerce acquirer.

  • Gilat Satellite Networks Ltd Initiation

    William Blair initiated research coverage of Gilat Satellite Networks Ltd. (GILT $4.96), an Israel-based provider of satellite communications infrastructure.

  • AAR Corp Initiation

    William Blair initiated research coverage of AAR Corp. (AIR $57.14), a provider of supply chain and maintenance, repair, and overhaul (MRO) services for commercial aviation and government customers.

  • CARGO Therapeutics Inc Initiation

    William Blair initiated research coverage of Cargo Therapeutics, Inc. (CRGX $16.23), a clinical-stage biotech company focused on developing next-generation CAR-T therapies for the treatment of cancer.

  • Primo Water Corporation Initiation

    William Blair initiated research coverage of Primo Water Corporation (PRMW $27.67), a leading North America–focused pure-play water solutions provider.

  • Keros Therapeutics Inc Initiation

    William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-β superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures